Design Therapeutics, Inc. (DSGN) Q3 2024 Earnings
DSGN·Reported November 7, 2024·Before market open
Diluted EPS came in at $-0.23, beat the $-0.26 consensus by $0.03.
Diluted EPS
$-0.23beat by $0.03
Consensus: $-0.26
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Design Therapeutics, Inc.'s Q3 2024 earnings report.
Design Therapeutics, Inc. (DSGN) reported Q3 2024 earnings on November 7, 2024 before market open.
Design Therapeutics, Inc. reported diluted EPS of $-0.23 for Q3 2024.
EPS beat the consensus estimate of $-0.26 by $0.03.
You can read the 10-Q periodic report (0000950170-24-123349) directly on SEC EDGAR. The filing index links above go to sec.gov.